In acute myeloid leukemia (AML), the link between ferroptosis and the immune microenvironment has profound clinical significance. The objective of this study was to investigate the role of ferroptosis-immune related genes (FIRGs) in predicting the prognosis and therapeutic sensitivity in patients with AML. Using The Cancer Genome Atlas dataset, single sample gene set enrichment analysis was performed to calculate the ferroptosis score of AML samples. To search for FIRGs, differentially expressed genes between the high- and low-ferroptosis score groups were identified and then cross-screened with immune related genes. Univariate Cox and LASSO regression analyses were performed on the FIRGs to establish a prognostic risk score model with five signature FIRGs (BMP2, CCL3, EBI3, ELANE, and S100A6). The prognostic risk score model was then used to divide the patients into high- and low-risk groups. For external validation, two Gene Expression Omnibus cohorts were employed. Overall survival was poorer in the high-risk group than in the low-risk group. The novel risk score model was an independent prognostic factor for overall survival in patients with AML. Infiltrating immune cells were also linked to high-risk scores. Treatment targeting programmed cell death protein 1 may be more effective in high-risk patients. This FIRG-based prognostic risk model may aid in optimizing prognostic risk stratification and treatment of AML.
Citation: Xing Guo, Xiaogang Zhou. Risk stratification of acute myeloid leukemia: Assessment using a novel prediction model based on ferroptosis-immune related genes[J]. Mathematical Biosciences and Engineering, 2022, 19(12): 11821-11839. doi: 10.3934/mbe.2022551
[1] | Ridha Dida, Hamid Boulares, Bahaaeldin Abdalla, Manar A. Alqudah, Thabet Abdeljawad . On positive solutions of fractional pantograph equations within function-dependent kernel Caputo derivatives. AIMS Mathematics, 2023, 8(10): 23032-23045. doi: 10.3934/math.20231172 |
[2] | Hamid Boulares, Manar A. Alqudah, Thabet Abdeljawad . Existence of solutions for a semipositone fractional boundary value pantograph problem. AIMS Mathematics, 2022, 7(10): 19510-19519. doi: 10.3934/math.20221070 |
[3] | Reny George, Fahad Al-shammari, Mehran Ghaderi, Shahram Rezapour . On the boundedness of the solution set for the ψ-Caputo fractional pantograph equation with a measure of non-compactness via simulation analysis. AIMS Mathematics, 2023, 8(9): 20125-20142. doi: 10.3934/math.20231025 |
[4] | Saeed M. Ali, Mohammed S. Abdo, Bhausaheb Sontakke, Kamal Shah, Thabet Abdeljawad . New results on a coupled system for second-order pantograph equations with ABC fractional derivatives. AIMS Mathematics, 2022, 7(10): 19520-19538. doi: 10.3934/math.20221071 |
[5] | Weerawat Sudsutad, Chatthai Thaiprayoon, Aphirak Aphithana, Jutarat Kongson, Weerapan Sae-dan . Qualitative results and numerical approximations of the (k,ψ)-Caputo proportional fractional differential equations and applications to blood alcohol levels model. AIMS Mathematics, 2024, 9(12): 34013-34041. doi: 10.3934/math.20241622 |
[6] | Choukri Derbazi, Zidane Baitiche, Mohammed S. Abdo, Thabet Abdeljawad . Qualitative analysis of fractional relaxation equation and coupled system with Ψ-Caputo fractional derivative in Banach spaces. AIMS Mathematics, 2021, 6(3): 2486-2509. doi: 10.3934/math.2021151 |
[7] | Abdelkader Moumen, Ramsha Shafqat, Zakia Hammouch, Azmat Ullah Khan Niazi, Mdi Begum Jeelani . Stability results for fractional integral pantograph differential equations involving two Caputo operators. AIMS Mathematics, 2023, 8(3): 6009-6025. doi: 10.3934/math.2023303 |
[8] | Iyad Suwan, Mohammed S. Abdo, Thabet Abdeljawad, Mohammed M. Matar, Abdellatif Boutiara, Mohammed A. Almalahi . Existence theorems for Ψ-fractional hybrid systems with periodic boundary conditions. AIMS Mathematics, 2022, 7(1): 171-186. doi: 10.3934/math.2022010 |
[9] | Mohamed Houas, Kirti Kaushik, Anoop Kumar, Aziz Khan, Thabet Abdeljawad . Existence and stability results of pantograph equation with three sequential fractional derivatives. AIMS Mathematics, 2023, 8(3): 5216-5232. doi: 10.3934/math.2023262 |
[10] | Karim Guida, Lahcen Ibnelazyz, Khalid Hilal, Said Melliani . Existence and uniqueness results for sequential ψ-Hilfer fractional pantograph differential equations with mixed nonlocal boundary conditions. AIMS Mathematics, 2021, 6(8): 8239-8255. doi: 10.3934/math.2021477 |
In acute myeloid leukemia (AML), the link between ferroptosis and the immune microenvironment has profound clinical significance. The objective of this study was to investigate the role of ferroptosis-immune related genes (FIRGs) in predicting the prognosis and therapeutic sensitivity in patients with AML. Using The Cancer Genome Atlas dataset, single sample gene set enrichment analysis was performed to calculate the ferroptosis score of AML samples. To search for FIRGs, differentially expressed genes between the high- and low-ferroptosis score groups were identified and then cross-screened with immune related genes. Univariate Cox and LASSO regression analyses were performed on the FIRGs to establish a prognostic risk score model with five signature FIRGs (BMP2, CCL3, EBI3, ELANE, and S100A6). The prognostic risk score model was then used to divide the patients into high- and low-risk groups. For external validation, two Gene Expression Omnibus cohorts were employed. Overall survival was poorer in the high-risk group than in the low-risk group. The novel risk score model was an independent prognostic factor for overall survival in patients with AML. Infiltrating immune cells were also linked to high-risk scores. Treatment targeting programmed cell death protein 1 may be more effective in high-risk patients. This FIRG-based prognostic risk model may aid in optimizing prognostic risk stratification and treatment of AML.
Recently, fractional calculus methods became of great interest, because it is a powerful tool for calculating the derivation of multiples systems. These methods study real world phenomena in many areas of natural sciences including biomedical, radiography, biology, chemistry, and physics [1,2,3,4,5,6,7]. Abundant publications focus on the Caputo fractional derivative (CFD) and the Caputo-Hadamard derivative. Additionally, other generalization of the previous derivatives, such as Ψ-Caputo, study the existence of solutions to some FDEs (see [8,9,10,11,12,13,14]).
In general, an m-point fractional boundary problem involves a fractional differential equation with fractional boundary conditions that are specified at m different points on the boundary of a domain. The fractional derivative is defined using the Riemann-Liouville fractional derivative or the Caputo fractional derivative. Solving these types of problems can be challenging due to the non-local nature of fractional derivatives. However, there are various numerical and analytical methods available for solving such problems, including the spectral method, the finite difference method, the finite element method, and the homotopy analysis method. The applications of m-point fractional boundary problems can be found in various fields, including physics, engineering, finance, and biology. These problems are useful in modeling and analyzing phenomena that exhibit non-local behavior or involve memory effects (see [15,16,17,18]).
Pantograph equations are a set of differential equations that describe the motion of a pantograph, which is a mechanism used for copying and scaling drawings or diagrams. The equations are based on the assumption that the pantograph arms are rigid and do not deform during operation, we can simply say that see [19]. One important application of the pantograph equations is in the field of drafting and technical drawing. Before the advent of computer-aided design (CAD) software, pantographs were commonly used to produce scaled copies of drawings and diagrams. By adjusting the lengths of the arms and the position of the stylus, a pantograph can produce copies that are larger or smaller than the original [20], electrodynamics [21] and electrical pantograph of locomotive [22].
Many authors studied a huge number of positive solutions for nonlinear fractional BVP using fixed point theorems (FPTs) such as SFPT, Leggett-Williams and Guo-Krasnosel'skii (see [23,24]). Some studies addressed the sign-changing of solution of BVPs [25,26,27,28,29].
In this work, we use Schauder's fixed point theorem (SFPT) to solve the semipostone multipoint Ψ-Caputo fractional pantograph problem
Dν;ψrϰ(ς)+F(ς,ϰ(ς),ϰ(r+λς))=0, ς in (r,ℑ) | (1.1) |
ϰ(r)=ϑ1, ϰ(ℑ)=m−2∑i=1ζiϰ(ηi)+ϑ2, ϑi∈R, i∈{1,2}, | (1.2) |
where λ∈(0,ℑ−rℑ),Dν;ψr is Ψ-Caputo fractional derivative (Ψ-CFD) of order ν, 1<ν≤2, ζi∈R+(1≤i≤m−2) such that 0<Σm−2i=1ζi<1, ηi∈(r,ℑ), and F:[r,ℑ]×R×R→R.
The most important aspect of this research is to prove the existence of a positive solution of the above m-point FBVP. Note that in [30], the author considered a two-point BVP using Liouville-Caputo derivative.
The article is organized as follows. In the next section, we provide some basic definitions and arguments pertinent to fractional calculus (FC). Section 3 is devoted to proving the the main result and an illustrative example is given in Section 4.
In the sequel, Ψ denotes an increasing map Ψ:[r1,r2]→R via Ψ′(ς)≠0, ∀ ς, and [α] indicates the integer part of the real number α.
Definition 2.1. [4,5] Suppose the continuous function ϰ:(0,∞)→R. We define (RLFD) the Riemann-Liouville fractional derivative of order α>0,n=[α]+1 by
RLDα0+ϰ(ς)=1Γ(n−α)(ddς)n∫ς0(ς−τ)n−α−1ϰ(τ)dτ, |
where n−1<α<n.
Definition 2.2. [4,5] The Ψ-Riemann-Liouville fractional integral (Ψ-RLFI) of order α>0 of a continuous function ϰ:[r,ℑ]→R is defined by
Iα;Ψrϰ(ς)=∫ςr(Ψ(ς)−Ψ(τ))α−1Γ(α)Ψ′(τ)ϰ(τ)dτ. |
Definition 2.3. [4,5] The CFD of order α>0 of a function ϰ:[0,+∞)→R is defined by
Dαϰ(ς)=1Γ(n−α)∫ς0(ς−τ)n−α−1ϰ(n)(τ)dτ, α∈(n−1,n),n∈N. |
Definition 2.4. [4,5] We define the Ψ-CFD of order α>0 of a continuous function ϰ:[r,ℑ]→R by
Dα;Ψrϰ(ς)=∫ςr(Ψ(ς)−Ψ(τ))n−α−1Γ(n−α)Ψ′(τ)∂nΨϰ(τ)dτ, ς>r, α∈(n−1,n), |
where ∂nΨ=(1Ψ′(ς)ddς)n,n∈N.
Lemma 2.1. [4,5] Suppose q,ℓ>0, and ϰinC([r,ℑ],R). Then ∀ς∈[r,ℑ] and by assuming Fr(ς)=Ψ(ς)−Ψ(r), we have
1) Iq;ΨrIℓ;Ψrϰ(ς)=Iq+ℓ;Ψrϰ(ς),
2) Dq;ΨrIq;Ψrϰ(ς)=ϰ(ς),
3) Iq;Ψr(Fr(ς))ℓ−1=Γ(ℓ)Γ(ℓ+q)(Fr(ς))ℓ+q−1,
4) Dq;Ψr(Fr(ς))ℓ−1=Γ(ℓ)Γ(ℓ−q)(Fr(ς))ℓ−q−1,
5) Dq;Ψr(Fr(ς))k=0, k=0,…,n−1, n∈N, qin(n−1,n].
Lemma 2.2. [4,5] Let n−1<α1≤n,α2>0, r>0, ϰ∈L(r,ℑ), Dα1;Ψrϰ∈L(r,ℑ). Then the differential equation
Dα1;Ψrϰ=0 |
has the unique solution
ϰ(ς)=W0+W1(Ψ(ς)−Ψ(r))+W2(Ψ(ς)−Ψ(r))2+⋯+Wn−1(Ψ(ς)−Ψ(r))n−1, |
and
Iα1;ΨrDα1;Ψrϰ(ς)=ϰ(ς)+W0+W1(Ψ(ς)−Ψ(r))+W2(Ψ(ς)−Ψ(r))2+⋯+Wn−1(Ψ(ς)−Ψ(r))n−1, |
with Wℓ∈R, ℓ∈{0,1,…,n−1}.
Furthermore,
Dα1;ΨrIα1;Ψrϰ(ς)=ϰ(ς), |
and
Iα1;ΨrIα2;Ψrϰ(ς)=Iα2;ΨrIα1;Ψrϰ(ς)=Iα1+α2;Ψrϰ(ς). |
Here we will deal with the FDE solution of (1.1) and (1.2), by considering the solution of
−Dν;ψrϰ(ς)=h(ς), | (2.1) |
bounded by the condition (1.2). We set
Δ:=Ψ(ℑ)−Ψ(r)−Σm−2i=1ζi(Ψ(ηi)−Ψ(r)). |
Lemma 2.3. Let ν∈(1,2] and ς∈[r,ℑ]. Then, the FBVP (2.1) and (1.2) have a solution ϰ of the form
ϰ(ς)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+∫ℑrϖ(ς,τ)h(τ)Ψ′(τ)dτ, |
where
ϖ(ς,τ)=1Γ(ν){[(Ψ(ℑ)−Ψ(r))ν−1−Σm−2j=iζj(Ψ(ηj)−Ψ(τ))ν−1]Ψ(ς)−Ψ(r)Δ−(Ψ(ς)−Ψ(τ))ν−1,τ≤ς,ηi−1<τ≤ηi,[(Ψ(ℑ)−Ψ(τ))ν−1−Σm−2j=iζj(Ψ(ηj)−Ψ(τ))ν−1]Ψ(ℑ)−Ψ(r)Δ,ς≤τ,ηi−1<τ≤ηi, | (2.2) |
i=1,2,...,m−2.
Proof. According to the Lemma 2.2 the solution of Dν;ψrϰ(ς)=−h(ς) is given by
ϰ(ς)=−1Γ(ν)∫ςr(Ψ(ς)−Ψ(τ))ν−1h(τ)Ψ′(τ)dτ+c0+c1(Ψ(ς)−Ψ(r)), | (2.3) |
where c0,c1∈R. Since ϰ(r)=ϑ1 and ϰ(ℑ)=∑m−2i=1ζiϰ(ηi)+ϑ2, we get c0=ϑ1 and
c1=1Δ(−1Γ(ν)m−2∑i=1ζi∫ηjr(Ψ(ηi)−Ψ(τ))ν−1h(τ)Ψ′(τ)dτ+1Γ(ν)∫ℑr(Ψ(ℑ)−Ψ(τ))ν−1h(τ)Ψ′(τ)dτ+ϑ1[m−2∑i=1ζi−1]+ϑ2). |
By substituting c0,c1 into Eq (2.3) we find,
ϰ(ς)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+(Ψ(ς)−Ψ(r))Δϑ2−1Γ(ν)(∫ςr(Ψ(ς)−Ψ(τ))ν−1h(τ)Ψ′(τ)dτ+(Ψ(ς)−Ψ(r))Δm−2∑i=1ζi∫ηjr(Ψ(ηi)−Ψ(τ))ν−1h(τ)Ψ′(τ)dτ−Ψ(ς)−Ψ(r)Δ∫ℑr(Ψ(ℑ)−Ψ(τ))ν−1h(τ)Ψ′(τ)dτ)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+(Ψ(ς)−Ψ(r))Δϑ2+∫ℑrϖ(ς,τ)h(τ)Ψ′(τ)dτ, |
where ϖ(ς,τ) is given by (2.2). Hence the required result.
Lemma 2.4. If 0<∑m−2i=1ζi<1, then
i) Δ>0,
ii) (Ψ(ℑ)−Ψ(τ))ν−1−∑m−2j=iζj(Ψ(ηj)−Ψ(τ))ν−1>0.
Proof. i) Since ηi<ℑ, we have
ζi(Ψ(ηi)−Ψ(r))<ζi(Ψ(ℑ)−Ψ(r)), |
−m−2∑i=1ζi(Ψ(ηi)−Ψ(r))>−m−2∑i=1ζi(Ψ(ℑ)−Ψ(r)), |
Ψ(ℑ)−Ψ(r)−m−2∑i=1ζi(Ψ(ηi)−Ψ(r))>Ψ(ℑ)−Ψ(r)−m−2∑i=1ζi(Ψ(ℑ)−Ψ(r))=(Ψ(ℑ)−Ψ(r))[1−m−2∑i=1ζi]. |
If 1−Σm−2i=1ζi>0, then (Ψ(ℑ)−Ψ(r))−Σm−2i=1ζi(Ψ(ηi)−Ψ(r))>0. So we have Δ>0.
ii) Since 0<ν−1≤1, we have (Ψ(ηi)−Ψ(τ))ν−1<(Ψ(ℑ)−Ψ(τ))ν−1. Then we obtain
m−2∑j=iζj(Ψ(ηj)−Ψ(τ))ν−1<m−2∑j=iζj(Ψ(ℑ)−Ψ(τ))ν−1≤(Ψ(ℑ)−Ψ(τ))ν−1m−2∑i=1ζi<(Ψ(ℑ)−Ψ(τ))ν−1, |
and so
(Ψ(ℑ)−Ψ(τ))ν−1−m−2∑j=iζj(Ψ(ηj)−Ψ(τ))ν−1>0. |
Remark 2.1. Note that ∫ℑrϖ(ς,τ)Ψ′(τ)dτ is bounded ∀ς∈[r,ℑ]. Indeed
∫ℑr|ϖ(ς,τ)|Ψ′(τ)dτ≤1Γ(ν)∫ςr(Ψ(ς)−Ψ(τ))ν−1Ψ′(τ)dτ+Ψ(ς)−Ψ(r)Γ(ν)Δm−2∑i=1ζi∫ηir(Ψ(ηj)−Ψ(τ))ν−1Ψ′(τ)dτ+Ψ(ς)−Ψ(r)ΔΓ(ν)∫ℑr(Ψ(ℑ)−Ψ(τ))ν−1Ψ′(τ)dτ=(Ψ(ς)−Ψ(r))νΓ(ν+1)+Ψ(ς)−Ψ(r)ΔΓ(ν+1)m−2∑i=1ζi(Ψ(ηi)−Ψ(r))ν+Ψ(ς)−Ψ(r)ΔΓ(ν+1)(Ψ(ℑ)−Ψ(r))ν≤(Ψ(ℑ)−Ψ(r))νΓ(ν+1)+Ψ(ℑ)−Ψ(r)ΔΓ(ν+1)m−2∑i=1ζi(Ψ(ηi)−Ψ(r))ν+(Ψ(ℑ)−Ψ(r))ν+1ΔΓ(ν+1)=M. | (2.4) |
Remark 2.2. Suppose Υ(ς)∈L1[r,ℑ], and w(ς) verify
{Dν;ψrw(ς)+Υ(ς)=0,w(r)=0, w(ℑ)=Σm−2i=1ζiw(ηi), | (2.5) |
then w(ς)=∫ℑrϖ(ς,τ)Υ(τ)Ψ′(τ)dτ.
Next we recall the Schauder fixed point theorem.
Theorem 2.1. [23] [SFPT] Consider the Banach space Ω. Assume ℵ bounded, convex, closed subset in Ω. If ϝ:ℵ→ℵ is compact, then it has a fixed point in ℵ.
We start this section by listing two conditions which will be used in the sequel.
● (Σ1) There exists a nonnegative function Υ∈L1[r,ℑ] such that ∫ℑrΥ(ς)dς>0 and F(ς,ϰ,v)≥−Υ(ς) for all (ς,ϰ,v)∈[r,ℑ]×R×R.
● (Σ2) G(ς,ϰ,v)≠0, for (ς,ϰ,v)∈[r,ℑ]×R×R.
Let ℵ=C([r,ℑ],R) the Banach space of CFs (continuous functions) with the following norm
‖ϰ‖=sup{|ϰ(ς)|:ς∈[r,ℑ]}. |
First of all, it seems that the FDE below is valid
Dν;ψrϰ(ς)+G(ς,ϰ∗(ς),ϰ∗(r+λς))=0, ς∈[r,ℑ]. | (3.1) |
Here the existence of solution satisfying the condition (1.2), such that G:[r,ℑ]×R×R→R
G(ς,z1,z2)={F(ς,z1,z2)+Υ(ς), z1,z2≥0,F(ς,0,0)+Υ(ς), z1≤0 or z2≤0, | (3.2) |
and ϰ∗(ς)=max{(ϰ−w)(ς),0}, hence the problem (2.5) has w as unique solution. The mapping Q:ℵ→ℵ accompanied with the (3.1) and (1.2) defined as
(Qϰ)(ς)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+∫ℑrϖ(ς,τ)G(ς,ϰ∗(τ),ϰ∗(r+λτ))Ψ′(τ)dτ, | (3.3) |
where the relation (2.2) define ϖ(ς,τ). The existence of solution of the problems (3.1) and (1.2) give the existence of a fixed point for Q.
Theorem 3.1. Suppose the conditions (Σ1) and (Σ2) hold. If there exists ρ>0 such that
[1+Σm−2i=1ζi−1Δ(Ψ(ℑ)−Ψ(r))]ϑ1+Ψ(ℑ)−Ψ(r)Δϑ2+LM≤ρ, |
where L≥max{|G(ς,ϰ,v)|:ς∈[r,ℑ], |ϰ|,|v|≤ρ} and M is defined in (2.4), then, the problems (3.1) and (3.2) have a solution ϰ(ς).
Proof. Since P:={ϰ∈ℵ:‖ϰ‖≤ρ} is a convex, closed and bounded subset of B described in the Eq (3.3), the SFPT is applicable to P. Define Q:P→ℵ by (3.3). Clearly Q is continuous mapping. We claim that range of Q is subset of P. Suppose ϰ∈P and let ϰ∗(ς)≤ϰ(ς)≤ρ, ∀ς∈[r,ℑ]. So
|Qϰ(ς)|=|[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+∫ℑrϖ(ς,τ)G(τ,ϰ∗(τ),ϰ∗(r+λτ))Ψ′(τ)dτ|≤[1+Σm−2i=1ζi−1Δ(Ψ(ℑ)−Ψ(r))]ϑ1+Ψ(ℑ)−Ψ(r)Δϑ2+LM≤ρ, |
for all ς∈[r,ℑ]. This indicates that ‖Qϰ‖≤ρ, which proves our claim. Thus, by using the Arzela-Ascoli theorem, Q:ℵ→ℵ is compact. As a result of SFPT, Q has a fixed point ϰ in P. Hence, the problems (3.1) and (1.2) has ϰ as solution.
Lemma 3.1. ϰ∗(ς) is a solution of the FBVP (1.1), (1.2) and ϰ(ς)>w(ς) for every ς∈[r,ℑ] iff the positive solution of FBVP (3.1) and (1.2) is ϰ=ϰ∗+w.
Proof. Let ϰ(ς) be a solution of FBVP (3.1) and (1.2). Then
ϰ(ς)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+(Ψ(ς)−Ψ(r))Δϑ2+1Γ(ν)∫ℑrϖ(ς,τ)G(τ,ϰ∗(τ),ϰ∗(r+λτ))Ψ′(τ)dτ=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+1Γ(ν)∫ℑrϖ(ς,τ)(F(τ,ϰ∗(τ),ϰ∗(r+λτ))+p(τ))Ψ′(τ)dτ=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+1Γ(ν)∫ℑrϖ(ς,τ)F(τ,(ϰ−w)(τ),(ϰ−w)(r+λτ))Ψ′(τ)dτ+1Γ(ν)∫ℑrϖ(ς,τ)p(τ)Ψ′(τ)dτ=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+1Γ(ν)∫ℑrϖ(ς,τ)G(τ,(ϰ−w)(τ),(ϰ−w)(r+λτ))Ψ′(τ)dτ+w(ς). |
So,
ϰ(ς)−w(ς)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+1Γ(ν)∫ℑrϖ(ς,τ)F(τ,(ϰ−w)(τ),(ϰ−w)(r+λτ))Ψ′(τ)dτ. |
Then we get the existence of the solution with the condition
ϰ∗(ς)=[1+Σm−2i=1ζi−1Δ(Ψ(ς)−Ψ(r))]ϑ1+Ψ(ς)−Ψ(r)Δϑ2+1Γ(ν)∫ℑrϖ(ς,τ)F(τ,ϰ∗(τ),ϰ∗(r+λτ))Ψ′(τ)dτ. |
For the converse, if ϰ∗ is a solution of the FBVP (1.1) and (1.2), we get
Dν;ψr(ϰ∗(ς)+w(ς))=Dν;ψrϰ∗(ς)+Dν;ψrw(ς)=−F(ς,ϰ∗(ς),ϰ∗(r+λς))−p(ς)=−[F(ς,ϰ∗(ς),ϰ∗(r+λς))+p(ς)]=−G(ς,ϰ∗(ς),ϰ∗(r+λς)), |
which leads to
Dν;ψrϰ(ς)=−G(ς,ϰ∗(ς),ϰ∗(r+λς)). |
We easily see that
ϰ∗(r)=ϰ(r)−w(r)=ϰ(r)−0=ϑ1, |
i.e., ϰ(r)=ϑ1 and
ϰ∗(ℑ)=m−2∑i=1ζiϰ∗(ηi)+ϑ2, |
ϰ(ℑ)−w(ℑ)=m−2∑i=1ζiϰ(ηi)−m−2∑i=1ζjw(ηi)+ϑ2=m−2∑i=1ζi(ϰ(ηi)−w(ηi))+ϑ2. |
So,
ϰ(ℑ)=m−2∑i=1ζiϰ(ηi)+ϑ2. |
Thus ϰ(ς) is solution of the problem FBVP (3.1) and (3.2).
We propose the given FBVP as follows
D75ϰ(ς)+F(ς,ϰ(ς),ϰ(1+0.5ς))=0, ς∈(1,e), | (4.1) |
ϰ(1)=1, ϰ(e)=17ϰ(52)+15ϰ(74)+19ϰ(115)−1. | (4.2) |
Let Ψ(ς)=logς, where F(ς,ϰ(ς),ϰ(1+12ς))=ς1+ςarctan(ϰ(ς)+ϰ(1+12ς)).
Taking Υ(ς)=ς we get ∫e1ςdς=e2−12>0, then the hypotheses (Σ1) and (Σ2) hold. Evaluate Δ≅0.366, M≅3.25 we also get |G(ς,ϰ,v)|<π+e=L such that |ϰ|≤ρ, ρ=17, we could just confirm that
[1+Σm−2i=1ζi−1Δ(Ψ(ℑ)−Ψ(r))]ϑ1+Ψ(ℑ)−Ψ(r)Δϑ2+LM≅16.35≤17. | (4.3) |
By applying the Theorem 3.1 there exit a solution ϰ(ς) of the problem (4.1) and (4.2).
In this paper, we have provided the proof of BVP solutions to a nonlinear Ψ-Caputo fractional pantograph problem or for a semi-positone multi-point of (1.1) and(1.2). What's new here is that even using the generalized Ψ-Caputo fractional derivative, we were able to explicitly prove that there is one solution to this problem, and that in our findings, we utilize the SFPT. The results obtained in our work are significantly generalized and the exclusive result concern the semi-positone multi-point Ψ-Caputo fractional differential pantograph problem (1.1) and (1.2).
The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through Small Groups (RGP.1/350/43).
The authors declare no conflict of interest.
[1] |
K. Sasaki, F. Ravandi, T. M. Kadia, C. D. DiNardo, N. J. Short, G. Borthakur, et al., De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017, Cancer, 127 (2021), 2049–2061. https://doi.org/10.1002/cncr.33458 doi: 10.1002/cncr.33458
![]() |
[2] |
C. Ganzel, Z. Sun, L. D. Cripe, H. F. Fernandez, D. Douer, J. M. Rowe, et al., Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience, Am. J. Hematol., 93 (2018), 1074–1081. https://doi.org/10.1002/ajh.25162 doi: 10.1002/ajh.25162
![]() |
[3] |
S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, R. Skouta, E. M. Zaitsev, C. E. Gleason, et al., Ferroptosis: an iron-dependent form of nonapoptotic cell death, Cell, 149 (2012), 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042 doi: 10.1016/j.cell.2012.03.042
![]() |
[4] |
B. Hassannia, P. Vandenabeele, T. V. Berghe, Targeting ferroptosis to iron out cancer, Cancer Cell, 35 (2019), 830–849. https://doi.org/10.1016/j.ccell.2019.04.002 doi: 10.1016/j.ccell.2019.04.002
![]() |
[5] |
C. Liang, X. Zhang, M. Yang, X. Dong, Recent progress in ferroptosis inducers for cancer therapy, Adv. Mater., 31 (2019), e1904197. https://doi.org/10.1002/adma.201904197 doi: 10.1002/adma.201904197
![]() |
[6] |
F. Zhang, H. Liu, Identification of ferroptosis-associated genes exhibiting altered expression in pulmonary arterial hypertension, Math. Biosci. Eng., 18 (2021), 7619–7630. https://doi.org/10.3934/mbe.2021377 doi: 10.3934/mbe.2021377
![]() |
[7] |
R. Birsen, C. Larrue, J. Decroocq, N. Johnson, N. Guiraud, M. Gotanegre, et al., APR-246 induces early cell death by ferroptosis in acute myeloid leukemia, Haematologica, 107 (2022), 403–416. https://doi.org/10.3324/haematol.2020.259531 doi: 10.3324/haematol.2020.259531
![]() |
[8] |
D. S. Liu, C. P. Duong, S. Haupt, K. G. Montgomery, C. M. House, W. J. Azar, et al., Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation, Nat. Commun., 8 (2017), 14844. https://doi.org/10.1038/ncomms14844 doi: 10.1038/ncomms14844
![]() |
[9] |
H. Liu, Emerging agents and regimens for AML, J. Hematol. Oncol., 14 (2021), 49. https://doi.org/10.1186/s13045-021-01062-w doi: 10.1186/s13045-021-01062-w
![]() |
[10] |
Q. Zheng, Y. Zhao, J. Guo, S. Zhao, C. Fei, C. Xiao, et al., Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway, Cell Death Dis., 9 (2018), 515. https://doi.org/10.1038/s41419-018-0552-7 doi: 10.1038/s41419-018-0552-7
![]() |
[11] |
H. Tanaka, J. L. Espinoza, R. Fujiwara, S. Rai, Y. Morita, T. Ashida, et al., Excessive reactive iron impairs hematopoiesis by affecting both immature hematopoietic cells and stromal cells, Cells, 8 (2019). https://doi.org/10.3390/cells8030226 doi: 10.3390/cells8030226
![]() |
[12] |
V. D. Turubanova, I. V. Balalaeva, T. A. Mishchenko, E. Catanzaro, R. Alzeibak, N. N. Peskova, et al., Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine, J. Immunother. Cancer, 7 (2019), 350. https://doi.org/10.1186/s40425-019-0826-3 doi: 10.1186/s40425-019-0826-3
![]() |
[13] |
W. Wang, M. Green, J. E. Choi, M. Gijon, P. D. Kennedy, J. K. Johnson, et al., CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy, Nature, 569 (2019), 270–274. https://doi.org/10.1038/s41586-019-1170-y doi: 10.1038/s41586-019-1170-y
![]() |
[14] |
D. H. Kim, W. D. Kim, S. K. Kim, D. H. Moon, S. J. Lee, TGF-beta1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells, Cell Death Dis., 11 (2020), 406. https://doi.org/10.1038/s41419-020-2618-6 doi: 10.1038/s41419-020-2618-6
![]() |
[15] |
M. Manzano, A. Patil, A. Waldrop, S. S. Dave, A. Behdad, E. Gottwein, Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma, Nat. Commun., 9 (2018), 3263. https://doi.org/10.1038/s41467-018-05506-9 doi: 10.1038/s41467-018-05506-9
![]() |
[16] |
Y. Teng, B. Wang, D. Shang, N. Yang, Identification and validation of an immune and ferroptosis-combined index for non-small cell lung cancer, Front. Genet., 12 (2021), 764869. https://doi.org/10.3389/fgene.2021.764869 doi: 10.3389/fgene.2021.764869
![]() |
[17] |
B. Tang, R. Yan, J. Zhu, S. Cheng, C. Kong, W. Chen, et al., Integrative analysis of the molecular mechanisms, immunological features and immunotherapy response of ferroptosis regulators across 33 cancer types, Int. J. Biol. Sci., 18 (2022), 180–198. https://doi.org/10.7150/ijbs.64654 doi: 10.7150/ijbs.64654
![]() |
[18] |
B. N. Ostendorf, J. Bilanovic, N. Adaku, K. N. Tafreshian, B. Tavora, R. D. Vaughan, et al., Common germline variants of the human APOE gene modulate melanoma progression and survival, Nat. Med., 26 (2020), 1048–1053. https://doi.org/10.1038/s41591-020-0879-3 doi: 10.1038/s41591-020-0879-3
![]() |
[19] |
N. Kim, H. K. Kim, K. Lee, Y. Hong, J. H. Cho, J. W. Choi, et al., Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma, Nat. Commun., 11 (2020), 2285. https://doi.org/10.1038/s41467-020-16164-1 doi: 10.1038/s41467-020-16164-1
![]() |
[20] |
M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, et al., limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43 (2015), e47. https://doi.org/10.1093/nar/gkv007 doi: 10.1093/nar/gkv007
![]() |
[21] |
G. Yu, L. G. Wang, Y. Han, Q. Y. He, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, 16 (2012), 284–287. https://doi.org/10.1089/omi.2011.0118 doi: 10.1089/omi.2011.0118
![]() |
[22] |
N. Simon, J. Friedman, T. Hastie, R. Tibshirani, Regularization paths for cox's proportional hazards model via coordinate descent, J. Stat. Softw., 39 (2011), 1–13. https://doi.org/10.18637/jss.v039.i05 doi: 10.18637/jss.v039.i05
![]() |
[23] |
R. Tibshirani, The lasso method for variable selection in the Cox model, Stat. Med., 16 (1997), 385–395. https://doi.org/10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3 doi: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
![]() |
[24] |
S. Stanley, K. Vanarsa, S. Soliman, D. Habazi, C. Pedroza, G. Gidley, et al., Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities, Nat. Commun., 11 (2020), 2197. https://doi.org/10.1038/s41467-020-15986-3 doi: 10.1038/s41467-020-15986-3
![]() |
[25] |
Y. Wang, F. Hu, J. Y. Li, R. C. Nie, S. L. Chen, Y. Y. Cai, et al., Systematic construction and validation of a metabolic risk model for prognostic prediction in acute myelogenous leukemia, Front. Oncol., 10 (2020), 540. https://doi.org/10.3389/fonc.2020.00540 doi: 10.3389/fonc.2020.00540
![]() |
[26] |
S. Ullrich, R. Guigo, Dynamic changes in intron retention are tightly associated with regulation of splicing factors and proliferative activity during B-cell development, Nucleic Acids Res., 48 (2020), 1327–1340. https://doi.org/10.1093/nar/gkz1180 doi: 10.1093/nar/gkz1180
![]() |
[27] |
B. Bengsch, T. Ohtani, O. Khan, M. Setty, S. Manne, S. O'Brien, et al., Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells, Immunity, 48 (2018), 1029–1045. https://doi.org/10.1016/j.immuni.2018.04.026 doi: 10.1016/j.immuni.2018.04.026
![]() |
[28] |
X. Tekpli, T. Lien, A. H. Rossevold, D. Nebdal, E. Borgen, H. O. Ohnstad, et al., An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment, Nat. Commun., 10 (2019), 5499. https://doi.org/10.1038/s41467-019-13329-5 doi: 10.1038/s41467-019-13329-5
![]() |
[29] |
Y. Song, S. Tian, P. Zhang, N. Zhang, Y. Shen, J. Deng, Construction and validation of a novel ferroptosis-related prognostic model for acute myeloid leukemia, Front. Genet., 12 (2021), 708699. https://doi.org/10.3389/fgene.2021.708699 doi: 10.3389/fgene.2021.708699
![]() |
[30] |
N. Jiang, X. Zhang, Q. Chen, F. Kantawong, S. Wan, J. Liu, et al., Identification of a Mitochondria-related gene signature to predict the prognosis in AML, Front. Oncol., 12 (2022), 823831. https://doi.org/10.3389/fonc.2022.823831 doi: 10.3389/fonc.2022.823831
![]() |
[31] |
Z. Zhang, G. Cortese, C. Combescure, R. Marshall, M. Lee, H. J. Lim, et al., Overview of model validation for survival regression model with competing risks using melanoma study data, Ann. Transl. Med., 6 (2018), 325. https://doi.org/10.21037/atm.2018.07.38 doi: 10.21037/atm.2018.07.38
![]() |
[32] |
B. Yang, J. Shen, L. Xu, Y. Chen, X. Che, X. Qu, et al., Genome-wide identification of a novel eight-lncrna signature to improve prognostic prediction in head and neck squamous cell carcinoma, Front. Oncol., 9 (2019), 898. https://doi.org/10.3389/fonc.2019.00898 doi: 10.3389/fonc.2019.00898
![]() |
[33] |
G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, A. C. Obenauf, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, 39 (2013), 782–795. https://doi.org/10.1016/j.immuni.2013.10.003 doi: 10.1016/j.immuni.2013.10.003
![]() |
[34] |
P. Geeleher, N. J. Cox, R. S. Huang, Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines, Genome Biol., 15 (2014), R47. https://doi.org/10.1186/gb-2014-15-3-r47 doi: 10.1186/gb-2014-15-3-r47
![]() |
[35] |
X. Lu, L. Jiang, L. Zhang, Y. Zhu, W. Hu, J. Wang, et al., Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression, molecular features, and clinical outcome, Neoplasia, 21 (2019), 591–601. https://doi.org/10.1016/j.neo.2019.04.003 doi: 10.1016/j.neo.2019.04.003
![]() |
[36] |
D. Fu, B. Zhang, S. Wu, Y. Zhang, J. Xie, W. Ning, et al., Prognosis and characterization of immune microenvironment in acute myeloid leukemia through identification of an autophagy-related signature, Front. Immunol., 12 (2021), 695865. https://doi.org/10.3389/fimmu.2021.695865 doi: 10.3389/fimmu.2021.695865
![]() |
[37] |
Y. Yu, Y. Xie, L. Cao, L. Yang, M. Yang, M. T. Lotze, et al., The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents, Mol. Cell Oncol., 2 (2015), e1054549. https://doi.org/10.1080/23723556.2015.1054549 doi: 10.1080/23723556.2015.1054549
![]() |
[38] | F. Ye, W. Chai, M. Xie, M. Yang, Y. Yu, L. Cao, et al., HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS(Q61L) cells, Am. J. Cancer Res., 9 (2019), 730–739. |
[39] |
W. S. Yang, R. SriRamaratnam, M. E. Welsch, K. Shimada, R. Skouta, V. S. Viswanathan, et al., Regulation of ferroptotic cancer cell death by GPX4, Cell, 156 (2014), 317–331. https://doi.org/10.1016/j.cell.2013.12.010 doi: 10.1016/j.cell.2013.12.010
![]() |
[40] |
M. Wang, C. Zhang, T. Tian, T. Zhang, R. Wang, F. Han, et al., Increased regulatory t cells in peripheral blood of acute myeloid leukemia patients rely on tumor necrosis factor (tnf)-alpha-tnf receptor-2 pathway, Front. Immunol., 9 (2018), 1274. https://doi.org/10.3389/fimmu.2018.01274 doi: 10.3389/fimmu.2018.01274
![]() |
[41] |
I. Nepstad, K. J. Hatfield, I. S. Gronningsaeter, H. Reikvam, The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells, Int. J. Mol. Sci., 21 (2020). https://doi.org/10.3390/ijms21082907 doi: 10.3390/ijms21082907
![]() |
[42] |
Y. Han, A. Ye, L. Bi, J. Wu, K. Yu, S. Zhang, Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia, Cancer Sci., 105 (2014), 933–942. https://doi.org/10.1111/cas.12459 doi: 10.1111/cas.12459
![]() |
[43] |
T. A. Gruber, A. L. Gedman, J. Zhang, C. S. Koss, S. Marada, H. Q. Ta, et al., An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia, Cancer Cell, 22 (2012), 683–697. https://doi.org/10.1016/j.ccr.2012.10.007 doi: 10.1016/j.ccr.2012.10.007
![]() |
[44] |
F. Zylbersztejn, M. Flores-Violante, T. Voeltzel, F. E. Nicolini, S. Lefort, V. Maguer-Satta, The BMP pathway: A unique tool to decode the origin and progression of leukemia, Exp. Hematol., 61 (2018), 36–44. https://doi.org/10.1016/j.exphem.2018.02.005 doi: 10.1016/j.exphem.2018.02.005
![]() |
[45] |
Y. Wang, A. Gao, H. Zhao, P. Lu, H. Cheng, F. Dong, et al., Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha/CCL3, Leukemia, 30 (2016), 1897–1908. https://doi.org/10.1038/leu.2016.81 doi: 10.1038/leu.2016.81
![]() |
[46] |
O. Devergne, M. Birkenbach, E. Kieff, Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin, Proc. Natl. Acad. Sci. U S A, 94 (1997), 12041–12046. https://doi.org/10.1073/pnas.94.22.12041 doi: 10.1073/pnas.94.22.12041
![]() |
[47] |
Q. Tao, Y. Pan, Y. Wang, H. Wang, S. Xiong, Q. Li, et al., Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts, Int. J. Cancer, 137 (2015), 2384–2393. https://doi.org/10.1002/ijc.29563 doi: 10.1002/ijc.29563
![]() |
[48] |
H. Tamai, H. Yamaguchi, K. Miyake, M. Takatori, T. Kitano, S. Yamanaka, et al., Amlexanox downregulates S100A6 to sensitize KMT2A/AFF1-positive acute lymphoblastic leukemia to tnfalpha treatment, Cancer Res., 77 (2017), 4426–4433. https://doi.org/10.1158/0008-5472.CAN-16-2974 doi: 10.1158/0008-5472.CAN-16-2974
![]() |
[49] |
C. Ustun, J. S. Miller, D. H. Munn, D. J. Weisdorf, B. R. Blazar, Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?, Blood, 118 (2011), 5084–5095. https://doi.org/10.1182/blood-2011-07-365817 doi: 10.1182/blood-2011-07-365817
![]() |
[50] |
P. van Galen, V. Hovestadt, M. H. Wadsworth Ii, T. K. Hughes, G. K. Griffin, S. Battaglia, et al., Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity, Cell, 176 (2019), 1265–1281. https://doi.org/10.1016/j.cell.2019.01.031 doi: 10.1016/j.cell.2019.01.031
![]() |
[51] |
M. J. Szczepanski, M. Szajnik, M. Czystowska, M. Mandapathil, L. Strauss, A. Welsh, et al., Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia, Clin. Cancer Res., 15 (2009), 3325–3332. https://doi.org/10.1158/1078-0432.CCR-08-3010 doi: 10.1158/1078-0432.CCR-08-3010
![]() |
[52] |
X. Wang, J. Zheng, J. Liu, J. Yao, Y. He, X. Li, et al., Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients, Eur. J. Haematol., 75 (2005), 468–476. https://doi.org/10.1111/j.1600-0609.2005.00537.x doi: 10.1111/j.1600-0609.2005.00537.x
![]() |
[53] |
S. F. Hausler, I. M. del Barrio, J. Strohschein, P. A. Chandran, J. B. Engel, A. Honig, et al., Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity, Cancer Immunol. Immunother., 60 (2011), 1405–1418. https://doi.org/10.1007/s00262-011-1040-4 doi: 10.1007/s00262-011-1040-4
![]() |
[54] |
S. Yu, C. Liu, L. Zhang, B. Shan, T. Tian, Y. Hu, et al., Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia, Int. J. Mol. Sci., 15 (2014), 1927–1945. https://doi.org/10.3390/ijms15021927 doi: 10.3390/ijms15021927
![]() |
[55] |
H. A. Knaus, S. Berglund, H. Hackl, A. L. Blackford, J. F. Zeidner, R. Montiel-Esparza, et al., Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy, JCI Insight, 3 (2018). https://doi.org/10.1172/jci.insight.120974 doi: 10.1172/jci.insight.120974
![]() |
[56] |
M. Yi, D. Jiao, H. Xu, Q. Liu, W. Zhao, X. Han, et al., Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors, Mol. Cancer, 17 (2018), 129. https://doi.org/10.1186/s12943-018-0864-3 doi: 10.1186/s12943-018-0864-3
![]() |
![]() |
![]() |